Trajectory of Chemotherapy-Induced Peripheral Neuropathy and Its Predictive Factors in Breast Cancer Patients: A Prospective Longitudinal Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients shows varied progression patterns. Factors like BMI, hypertension, and depression influence CIPN risk, aiding early intervention strategies.
Area Of Science
- Oncology
- Neuroscience
- Clinical Research
Background
- Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity in cancer patients.
- Understanding CIPN trajectory patterns is crucial for managing treatment and improving patient outcomes.
Purpose Of The Study
- To identify distinct trajectory patterns of CIPN in breast cancer patients.
- To investigate the influencing factors associated with these CIPN trajectories using latent class growth analysis (LCGA).
Main Methods
- Latent class growth models (LCGMs) were employed to analyze CIPN progression in 350 breast cancer patients.
- Data on demographics, disease characteristics, lifestyle, and psychological status were collected.
- CIPN was assessed at five time points during chemotherapy cycles.
Main Results
- Three CIPN trajectory groups were identified: low-risk stable (42.3%), moderate-risk progressive (41.4%), and high-risk rapidly progressing (16.3%).
- Predictive factors for moderate and high-risk groups included BMI, hypertension, depression, physical activity, social support, vitamin D levels, and nutritional status.
Conclusions
- Breast cancer patients exhibit heterogeneous CIPN progression patterns.
- Identifying high-risk patients early through factors like BMI, hypertension, and depression allows for timely interventions to mitigate CIPN severity.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...